New strategy may target common cancer driver with minimal side effects

Researchers have found a surprisingly common vulnerability in a broad variety of cancers and have begun designing drug compounds to exploit it, in a study led by investigators at Weill Cornell Medicine. The findings suggest the possibility of a potent, low-side-effect treatment that could benefit many patients with colorectal, breast and other cancer types.

Read it at Medical Xpress ↗

← Front page